1. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence 
Claus Hellerbrand, Andreas Pöppl, Arndt Hartmann, Jürgen Schölmerich, Guntram Lock 
Clinical Gastroenterology and Hepatology 
Volume 1, Issue 4, Pages (July 2003)
DOI: /S (03)

2. Figure 1
Serum ferritin levels in HCC patients with C282Y heterozygote (C282Y +/−) (n = 14) or C282Y wt (C282Y −/−) (n = 83) genotype. Bars represent median serum levels.
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )

3. Figure 2
Transferrin saturation (TFS) in HCC patients with C282Y heterozygote (C282Y +/−) or C282Y wt (C282Y −/−) genotype. Bars represent median TFS.
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )

4. Figure 3
Hepatic iron deposition comparing C282Y heterozygote (C282Y +/−) and wt (C282Y −/−) HCC patients. Iron deposition was analyzed in (A) HCC tissue (n = 113) and (B) nontumorous surrounding liver tissue (n = 83) using a semiquantitative histologic score.
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )